FDA approves Tecentriq after surgery for a type of stage III colon cancer
Published
Adding the immunotherapy to chemo cut the risk of the cancer returning or death by half in a 712-patient trial. It is for tumors with a specific genetic marker.
Source: Roche
This is a plain-language summary. Read the original source for full details.